Info

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the medical needs of patients with chronic and cardiovascular, and infectious diseases and cancer. The Company’s principal therapeutic platforms include Prostacyclin Analogs, Glycobiology Antiviral Agents and Monoclonal Antibodies. Its principal prostacyclin analog is Remodulin, a treprostinil-based compound for the treatment of cardiovascular disease. Remodulin (treprostinil sodium) Injection, has been approved by the United States Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH) in patients with New York Heart Association (NYHA) Class II-IV (moderate to severe) symptoms to diminish symptoms associated with exercise, and in other countries for similar use, and in most of Europe for the treatment of NYHA Class III patients with idiopathic or familial PAH.(Source: 10-K)